$RCKT
Rocket Pharmaceuticals, Inc. Common Stock
XNAS
Why is RCKT down today? It is at $3.48 (-4.66%), and our scanner flagged it 61 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment RCKT spikes, and full due diligence on RCKT — key stats, earnings, dilution and insider activity. Free.
Get free $RCKT alerts the moment volume spikes
Our scanner flagged $RCKT 61 times in the last 30 days. Create a free account to track $RCKT, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $3.48
- Change today
- -4.66%
- Previous close
- $3.65
- 52-week range
- $2.53 – $5.45
- Market cap
- $367M
- Institutional own.
- 99.9%
- Total held
- 99.9%
- Tradeable float
- 108K 0% of shares · after <1% insiders + 100% institutions
- Short interest
- 15.5M ▼ -6% vs prior · as of 2026-07-31
- Days to cover
- 11.9d
- Avg daily volume
- 2.6M
- Exchange
- XNAS
- 5mthin
- 579x
- 15mthin
- 579x
- 1hthin
- 579x
- 1D
- 0.2x
Get free RCKT + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $RCKT down today?
RCKT is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on RCKT today.
Likely catalystRocket Pharmaceuticals Reports Second Quarter 2026 Financial Results andReported FDA approval of KRESLADI™ and subsequent monetization of the Priority Review Voucher generated $180 million in non-dilutive capital; focused preparations are underwayReported Cash, cash equivalents and investments of approximately $283.7 million; expected cash runway into the second quarter of 2028Reported On June 12, 2026, Rocket announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. This substantial non-dilutive, from an SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
Insiders buying8 buys, 4 sells last 3 months (22/24 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Wilson Martin Officer | Sold (automatic/other) | -3K | sold 0.5% | 674K | $12K at $3.38 | Aug 13, 26 |
Shah Gaurav Officer | Sold (automatic/other) | -3K | sold 0.3% | 1.06M | $10K at $3.38 | Aug 13, 26 |
Chaudhuri Sarbani Officer | Sold (automatic/other) | -5K | sold 1.8% | 263K | $16K at $3.50 | Aug 11, 26 |
Stevens Christopher James Officer | Sold (automatic/other) | -37K 0.03% of company | sold 6.8% | 506K | $128K at $3.50 | Aug 11, 26 |
Southwell David P Director | Acquired (grant/award) | +150K 0.1% of company | added 100% | 205K | n/a | Aug 3, 26 |
Stevens Christopher James Officer | Acquired (grant/award) | +73K 0.07% of company | added 16% | 542K | n/a | Aug 3, 26 |
Boess Carsten Director | Acquired (grant/award) | +23K 0.02% of company | added 76% | 53K | n/a | Jun 18, 26 |
Southwell David P Director | Acquired (grant/award) | +23K 0.02% of company | added 72% | 55K | n/a | Jun 18, 26 |
Fong Peter Director | Acquired (grant/award) | +23K 0.02% of company | added 43% | 76K | n/a | Jun 18, 26 |
Malik Fady Ibraham Director | Acquired (grant/award) | +23K 0.02% of company | added 76% | 53K | n/a | Jun 18, 26 |
Wong Roderick Director | Acquired (grant/award) | +28K 0.03% of company | added 58% | 75K | n/a | Jun 18, 26 |
Dolsten Mikael Director | Acquired (grant/award) | +23K 0.02% of company | added 52% | 67K | n/a | Jun 18, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
UnavailableWe could not reach SEC EDGAR, so the dilution check did not run for $RCKT. This is not a clean result: there may be an offering, a registration or a shelf on file that we were unable to read. Check it yourself on SEC EDGAR before trading it.
$RCKT Sentiment
BearishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$RCKT Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
RCKT stock FAQ
Why is $RCKT down today?
RCKT is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on RCKT today.
What is the RCKT stock price today?
RCKT last traded at $3.48, down 4.66% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live RCKT alerts?
The RCKT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged RCKT 61 times in the last 30 days.
What exchange is RCKT on?
RCKT (Rocket Pharmaceuticals, Inc. Common Stock) trades on XNAS, with a market cap of about $367M.
Is RCKT good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge RCKT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.